{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:15:41Z","timestamp":1789143341112,"version":"build-2803163510"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00277-022-04777-z","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T01:02:17Z","timestamp":1645405337000},"page":"1587-1589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Durable response of therapy-related MDS\/AML with concomitant Waldenstr\u00f6m\u2019s macroglobulinemia treated with venetoclax and azacitidine"],"prefix":"10.1007","volume":"101","author":[{"given":"Mitsuhito","family":"Hirano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikako","family":"Tamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihito","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiru","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Onda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Shirouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-6920","authenticated-orcid":false,"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"4777_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER et al (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202\u2013208. https:\/\/doi.org\/10.1038\/nm.3048","journal-title":"Nat Med"},{"issue":"383","key":"4777_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"13","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 13(383):617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"4777_CR3","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr, Hou JZ et al (2019) Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol 37:1277\u20131284. https:\/\/doi.org\/10.1200\/JCO.18.01600","journal-title":"J Clin Oncol"},{"key":"4777_CR4","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B et al (2018) Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378:1107\u20131120. https:\/\/doi.org\/10.1056\/NEJMoa1713976","journal-title":"N Engl J Med"},{"issue":"124","key":"4777_CR5","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1182\/blood-2014-03-565135","volume":"28","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Kastritis E, Owen RG et al (2014) Treatment recommendations for patients with Waldenstr\u00f6m macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 28(124):1404\u20131411. https:\/\/doi.org\/10.1182\/blood-2014-03-565135","journal-title":"Blood"},{"key":"4777_CR6","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1111\/cas.14561","volume":"111","author":"N Sekiguchi","year":"2020","unstructured":"Sekiguchi N, Rai S, Munakata W et al (2020) A multicenter, open-label, phase II study of tirabrutinib (ONO\/GS-4059) in patients with Waldenstr\u00f6m\u2019s macroglobulinemia. Cancer Sci 111:3327\u20133337. https:\/\/doi.org\/10.1111\/cas.14561","journal-title":"Cancer Sci"},{"issue":"1","key":"4777_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3324\/haematol.2016.147728","volume":"102","author":"MC Minnema","year":"2017","unstructured":"Minnema MC, Kimby E, D\u2019Sa S et al (2017) Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica 102(1):43\u201351. https:\/\/doi.org\/10.3324\/haematol.2016.147728","journal-title":"Haematologica"},{"issue":"27","key":"4777_CR8","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","volume":"1","author":"MS Davids","year":"2021","unstructured":"Davids MS, Roberts AW, Kenkre VP et al (2021) Long-term follow-up of patients with relapsed or refractory non-Hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study. Clin Cancer Res 1(27):4690\u20134695. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4842","journal-title":"Clin Cancer Res"},{"key":"4777_CR9","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","volume":"7","author":"JJ Castillo","year":"2020","unstructured":"Castillo JJ, Advani RH, Branagan AR et al (2020) Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia. Lancet Haematol 7:e827\u2013e837. https:\/\/doi.org\/10.1016\/S2352-3026(20)30224-6","journal-title":"Lancet Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04777-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04777-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04777-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T09:03:47Z","timestamp":1655370227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04777-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["4777"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04777-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"assertion":[{"value":"6 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent has been obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent statement"}},{"value":"DM has received honoraria from Abbvie and Nippon Shinyaku, and research funding from Abbvie. Other authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}